- Home
- LTRN vs IGC Comparison
LTRN vs IGC Comparison
Compare LTRN & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LTRN
- IGC
- Stock Information
- Founded
- LTRN 2013
- IGC 2005
- Country
- LTRN United States
- IGC United States
- Employees
- LTRN N/A
- IGC N/A
- Industry
- LTRN Biotechnology: Pharmaceutical Preparations
- IGC Biotechnology: Pharmaceutical Preparations
- Sector
- LTRN Health Care
- IGC Health Care
- Exchange
- LTRN Nasdaq
- IGC Nasdaq
- Market Cap
- LTRN 36.0M
- IGC 39.8M
- IPO Year
- LTRN 2020
- IGC N/A
- Fundamental
- Price
- LTRN $4.10
- IGC $0.42
- Analyst Decision
- LTRN Strong Buy
- IGC Strong Buy
- Analyst Count
- LTRN 1
- IGC 2
- Target Price
- LTRN $25.00
- IGC $4.00
- AVG Volume (30 Days)
- LTRN 105.4K
- IGC 1.4M
- Earning Date
- LTRN 11-06-2025
- IGC 11-11-2025
- Dividend Yield
- LTRN N/A
- IGC N/A
- EPS Growth
- LTRN N/A
- IGC N/A
- EPS
- LTRN N/A
- IGC N/A
- Revenue
- LTRN N/A
- IGC $1,327,000.00
- Revenue This Year
- LTRN N/A
- IGC $15.26
- Revenue Next Year
- LTRN N/A
- IGC $3.41
- P/E Ratio
- LTRN N/A
- IGC N/A
- Revenue Growth
- LTRN N/A
- IGC 24.95
- 52 Week Low
- LTRN $2.55
- IGC $0.25
- 52 Week High
- LTRN $6.12
- IGC $0.50
- Technical
- Relative Strength Index (RSI)
- LTRN 48.41
- IGC 56.86
- Support Level
- LTRN $3.74
- IGC $0.38
- Resistance Level
- LTRN $4.26
- IGC $0.47
- Average True Range (ATR)
- LTRN 0.31
- IGC 0.04
- MACD
- LTRN -0.04
- IGC -0.00
- Stochastic Oscillator
- LTRN 47.51
- IGC 36.92
About LTRN Lantern Pharma Inc.
Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.